TIGIT
Showing 1 - 25 of 96
Advanced Solid Tumor Trial in Bengbu (HB0030 injection)
Recruiting
- Advanced Solid Tumor
- HB0030 injection
-
Bengbu, Anhui, Chinathe First Affiliated Hospital of Bengbu Medical College
Jan 20, 2023
Advanced Tumor Trial (PM1009 injection)
Not yet recruiting
- Advanced Tumor
- PM1009 injection
- (no location specified)
Nov 7, 2022
Metastatic Malignancy Trial in Houston (Atezolizumab, Tiragolumab)
Not yet recruiting
- Metastatic Malignancy
-
Houston, TexasM D Anderson Cancer Center
Dec 19, 2022
Advanced Solid Tumours Trial (PM1021, PM8001)
Not yet recruiting
- Advanced Solid Tumours
- PM1021, PM8001
- (no location specified)
Sep 12, 2022
Melanoma Trial in Pittsburgh (Zimberelimab, Domvanalimab)
Recruiting
- Melanoma
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Apr 11, 2022
Advanced Malignancies Trial in Beijing (IBI939, IBI939+ Sintilimab)
Active, not recruiting
- Advanced Malignancies
- IBI939
- IBI939+ Sintilimab
-
Beijing, ChinaPeking University Cancer Hospital & Institute
Oct 4, 2022
Locally Advanced or Metastatic Solid Tumors, NSCLC Trial in Australia (HLX301)
Recruiting
- Locally Advanced or Metastatic Solid Tumors
- Non-small Cell Lung Cancer
-
Blacktown, New South Wales, Australia
- +4 more
May 25, 2022
Solid Tumor, Adult Trial in Albury (Tiragolumab, Atezolizumab)
Not yet recruiting
- Solid Tumor, Adult
- Tiragolumab
- Atezolizumab
-
Albury, New South Wales, Australia
- +1 more
Aug 22, 2023
Pre-Eclampsia Trial (real time PCR)
Not yet recruiting
- Pre-Eclampsia
- real time PCR
- (no location specified)
Mar 22, 2022
Advanced Tumors Trial in Guangzhou (JS006 as Monotherapy, JS006 in combination with Toripalimab)
Recruiting
- Advanced Tumors
- JS006 as Monotherapy
- JS006 in combination with Toripalimab
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Sep 21, 2021
Advanced Solid Tumor, NSCLC, Hepatocellular Carcinoma Trial in Canton (CHS-006 (anti-TIGIT), toripalimab (anti-PD-1))
Not yet recruiting
- Advanced Solid Tumor
- +2 more
- CHS-006 (anti-TIGIT)
- toripalimab (anti-PD-1)
-
Canton, OhioGabrail Cancer and Research Center
Feb 23, 2023
Solid Tumor Trial in Guanzhou (BAT6021)
Recruiting
- Solid Tumor
-
Guanzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Jul 26, 2022
TIGIT in Patients With Chronic Myeloid Leukemia
Not yet recruiting
- Chronic Myeloid Leukemia
- flow cytometry test
- (no location specified)
Mar 25, 2021
Intrahepatic Cholangiocarcinoma Trial in Shanghai (GP+PD-1+Tight)
Withdrawn
- Intrahepatic Cholangiocarcinoma
-
Shanghai, Shanghai, ChinaZhongshan hospital, Fudan University
Mar 22, 2022
Advanced Cancer, Ovarian Cancer, Lung Cancer Trial in United States (Dose escalation: COM902 monotherapy., Evaluation of
Recruiting
- Advanced Cancer
- +6 more
- Dose escalation: COM902 monotherapy.
- +3 more
-
Grand Rapids, Michigan
- +5 more
Aug 8, 2022
Cancer, Carcinoma, Squamous Cell Carcinoma Trial in San Francisco (Atezolizumab, Tocilizumab, Tiragolumab)
Recruiting
- Cancer
- +3 more
- Atezolizumab
- +2 more
-
San Francisco, CaliforniaUniversity of San Francisco, California
Feb 1, 2022
Endometrial Tumors, Ovarian Cancer, Solid Tumor Trial in United States (COM701 in combination with BMS-986207 and nivolumab.)
Recruiting
- Endometrial Neoplasms
- +3 more
- COM701 in combination with BMS-986207 and nivolumab.
-
Chicago, Illinois
- +8 more
Aug 8, 2022